MRNA

The biotech Arcturus has shown how new self-copying mRNA technology could get many people vaccinated quickly.

Unlike previously used viral vector vaccines, mRNA vaccines don’t introduce live or dead virus into the body as a means of triggering antibody production. “mRNA vaccine technology for treating diseases isn’t going anywhere. “It’s a totally different ball game.”Research into mRNA technology for vaccines goes back decades, though the efforts improved within the last 10 years. “Every pharma company now is investing billions of dollars into developing these mRNA vaccines into the anti-cancer medicine,” Walter said. While no mRNA vaccine for cancer has gained approval from the U.S. Food and Drug Administration, there’s hope that the success of COVID-19 vaccines will help accelerate clinical research.

Stories about the continuing risks of the pandemic may create unintended harms.

mRNA-based medicine has been a decade in the making.

The FDA and CDC offered little guidance about who should get the newly authorized second COVID-19 booster shot. We break it down.

China will require mass distribution of an existing mRNA booster shot along with antivirals to adapt.

A new study found that COVID-19 can increase the risk for developing 20 cardiac problems, including stroke and heart attack. Dr. Tara Narula reports.

Indonesia hit a daily record high of more than 64,000 cases last week, superseding daily infections in the previous wave which peaked just under 57,000 in July.

Egypt, Kenya, Nigeria, Senegal, South Africa and Tunisia will be the first African countries to receive the technology required to produce mRNA vaccines on the continent

European Union leaders have lauded the bloc’s cooperation with Africa on vaccines in the fight against the coronavirus, but there is no sign they will move toward the temporary lifting of intellectual property rights protection for COVID-19 shots

A new study says a million lives could be saved if mRNA vaccines went to poorer countries.

Current trials are underway to use mRNA in fighting multiple different cancers.

Current trials are underway to use mRNA in fighting multiple different cancers.

Moderna applied for emergency approval of its Covid vaccine for 12- to 17-year-olds in June, but the FDA said its review wouldn't be completed before January.

Added benefits of booster doses were especially prominent among people 50 to 64 and those 65 and older, a second study looking at data from April to late December found. This is consistent with recent information from some Michigan health systems, reporting 85 to 95% of patients with COVID-19 have not had booster shots. About 95% of vaccinated patients with COVID-19 admitted to Southfield-based Beaumont Health’s eight hospitals have not received booster shots, Dr. Matthew Sims, director of infectious disease research, said Friday. In Michigan, about 47% of people who are fully vaccinated have gotten booster shots. Before omicron, only those at greater risk of severe outcomes were told they should receive booster shots.

Hospitals are now tracking the percentage of their COVID-19 patients who have received booster shots of the COVID-19 vaccine, and the rates are low, about 5 to 15% at some reporting health systems. Of those 33, five had received booster shots, Dr. Christine Nefcy, chief medical officer, said during a Tuesday COVID update. Of them, 51 were vaccinated and 17, about 14%, had received their primary doses and a booster. “The numbers strongly, strongly support this.”People with booster shots see decreased illness, decreased hospitalizations and, certainly, decreased deaths, he said. In Michigan, about 47% of people who are fully vaccinated have gotten booster shots.

In September 2020, regulators asked for extra safety data on the new mRNA vaccines. The human cost of that request is far from clear.

The Maryland company's vaccine will be the fifth available in South Korea, where 84 percent of the public is fully vaccinated.

While the vaccine-making technology has had impressive results, new shots that are simpler to make and easier to store may hold the key to ending the global pandemic.

Almost 17 million Americans have received the Johnson & Johnson COVID-19 vaccine, a huge number that seems to have been forgotten. Here is what to know now.

Health experts expect to see more “flurona” as flu cases rise and coronavirus cases continue to surge due to the omicron variant.

Researchers are looking at ways messenger RNA technology from COVID-19 vaccines can be used to fight other illnesses and diseases.

These are the stocks posting the largest moves before the bell.

Modern described the findings as reassuring, but said it will also continue to develop an omicron-specific booster candidate.

We still don’t how many shots we really need, or how often we’ll need them.

Almost all the vaccines in a study of seven different shots appeared to boost the immune response when used as a third dose.

Covid-19 booster shots are being rolled out in the U.S. and other countries in response to waning antibody levels in already vaccinated individuals, and the increased threat posed by the hyper-infectious delta variant of the coronavirus that causes the disease. Giving a third shot to healthy people is a contentious strategy, since many low- and middle-income countries have yet to immunize even a 10th of their population. From a scientific standpoint, though, there’s mounting evidence that it cou

The Biden administration's new vaccine mandate for businesses with at least 100 employees will kick in on January 4, but these six myths are still holding people back from getting vaccinated.

It’s possible that a good deal of the difference in the COVID vaccines’ performance can be summed up with a simple phrase: More is better.

Senegal and Rwanda have signed an agreement with German company BioNTech for the construction of its first start-to-finish factories to make messenger RNA vaccines in Africa.

KALAMAZOO, MI — The Kalamazoo County Health & Community Services Department is now offering booster doses from Moderna and Jonson & Johnson, the department announced on Monday, Oct. 25. COVID-19 vaccines continue to be widely available from local providers and pharmacies. The health department recommends people use www.vaccines.gov to find a vaccination location. Those eligible for a booster may choose which vaccine they receive as a booster dose. For questions about which booster to receive, the health department recommends speaking with your own health care provider for advice.

Covid-19 booster shots are being rolled out in the U.S. and other countries in response to waning antibody levels in already vaccinated individuals, and the increased threat posed by the hyper-infectious delta variant of the coronavirus that causes the disease. Giving a third shot to healthy people is a contentious strategy, since many low- and middle-income countries have yet to immunize even a 10th of their population. From a scientific standpoint, though, there’s mounting evidence that it cou

BioNTech’s founders preview the future of the technology that’s already (partially) saved the world.

The stocks making the biggest moves in premarket trading include Tesla, Moderna, Novavax, GM, and more.

The stocks making the biggest moves in premarket trading include Ford, Thor Industries, Applied Materials, and more.

The messy process leading to this moment sparked massive confusion about the booster program, critics say, and may distract from efforts to get first shots to the unvaccinated.

With the back and forth on boosters from government agencies, many Americans are wondering if they really need an extra shot. Here is what the science says about who needs a booster now — and why.

"You could possibly be saving two lives with vaccination," Dr. Jennifer Lighter said.

Since the start of this month, the number of eligible people vaccinated in Michigan increased about 1.5%. There were good reasons to expedite the vaccines development, said Dr. Elizabeth Lloyd, pediatric infectious disease expert at Michigan Medicine’s C.S. “So, the fact that we were able to make these vaccines quickly shouldn’t be of concern.”Scientists already knew much about coronaviruses. No vaccine is perfect, and the COVID-19 vaccines were never designed or expected to prevent all infections. It is preventing people from progressing from mild disease to severe disease,” said Dr. Russell Lampen, an infectious disease specialist at Spectrum Health.

When it became clear in early 2020 that the Sars-CoV-2 virus posed a pandemic threat, researchers who’d been exploring an innovative way to make vaccines saw an opportunity. Experimental messenger RNA vaccines, seen for years as potentially offering speed and flexibility to combat a fast-moving epidemic, were some of the first Covid-19 inoculations to move into human trials. The effort paid off when, late last year, vaccines from Moderna Inc. and the Pfizer Inc./BioNTech SE partnership were the

The Centers for Disease Control and Prevention (CDC) announced recently that many Americans will be able to receive booster shots. That came after it was announced that immunocompromised Americans will be eligible to receive a third dose of the mRNA vaccine even sooner. The main differences between a booster shot and a third dose of a COVID-19 shot is not due to differences in dosage, but differences in eligibility and timing. Even then, these individuals are only eligible to receive a booster shot eight months after they received their second dose of the vaccine. The booster shots were also created to make sure immunity does not wane over time as opposed to the third vaccine dose, which is meant for people who have not built strong enough immunity after the first vaccine dose.

"The benefits of COVID-19 vaccination undoubtedly outweigh the risks," Dr. Sean T. Liu told CBS News.

An open letter from 175 experts to President Biden made the ask. "We're not trying to be unreasonable," explains Dr. Paul Farmer, one of the signers. "We're trying to be optimistic and audacious."

The 14 million people who received a Johnson & Johnson shot are going to have to wait a few more weeks for answers on boosters due to lack of data, federal health officials said Wednesday. Why it matters: The CDC currently advises people to stay with the shot they had initially. The effects of mixing doses are still unclear, but "it is anticipated that vaccine boosters will likely be needed," the White House tweeted. Get market news worthy of your time with Axios Markets. Subscribe for free.Data

A CDC advisory group voted unanimously to allow immunocompromised people to get a third dose of a COVID-19 vaccine.

Mario Tama/GettyThe U.S. Food and Drug Administration on Thursday authorized vaccine-eligible Americans with immune problems to receive a third dose of the safe and effective two-dose COVID-19 vaccines.The move could lead to a surge in vaccinations as some of the most vulnerable Americans shore up their immune systems against increasingly dangerous new variants of the novel coronavirus. And experts broadly support it given the seemingly relentless surge of the Delta variant. But with some Americ

Robert Malone claims to have invented mRNA vaccines. Why is he trying so hard to undermine their use?

A new preprint study that raises concerns about the mRNA vaccines' effectiveness against Delta — particularly Pfizer's — has already grabbed the attention of top Biden administration officials. What they're saying: The study found the Pfizer vaccine was only 42% effective against infection in July, when the Delta variant was dominant. "If that's not a wakeup call, I don't know what is," a senior Biden official told Axios. Stay on top of the latest market trends and economic insights with Axios M

Vaccines don't ward off every single infection but they do massively lower the risk. Education Images/Universal Images Group via Getty ImagesIf you’ve been fully vaccinated against COVID-19, maybe you figured you no longer need to worry about contracting the coronavirus. But along with the rising number of new COVID-19 cases globally and growing concern about highly transmissible strains like the delta variant come reports of fully vaccinated people testing positive for COVID-19. Members of the

Pharmaceutical company BioNTech says it wants to use the mRNA technology behind its coronavirus vaccine to target malaria.

BioNTech said it plans to develop an mRNA-based vaccine to prevent malaria, a life-threatening disease that impacts millions of people worldwide each year.

The Johnson and Johnson COVID vaccine may not be as effective as vaccines that use mRNA technology (Pfizer and Moderna), according to a new study.

As the delta Covid variant spreads, Moderna co-founder Noubar Afeyan explains how his company was able to deploy an mRNA vaccine in less a year from the start of the pandemic.

Germany is recommending that all people who get a first shot of the AstraZeneca coronavirus vaccine switch to a different type of vaccine for their second shot. Health Minister Jens Spahn conferred with his colleagues from Germany's 16 states on Friday, the day after the country's standing committee on vaccination issued a draft recommendation. In a statement, the committee said that “according to current study results,” the immune response from a mixture of AstraZeneca with an mRNA vaccine was “significantly superior” to that from two doses of AstraZeneca.

A new study has found that some vaccines may offer COVID-19 immunity for years, especially for those who contracted and recovered from the virus before immunization.

The CDC’s vaccine advisory panel said that rate reports of heart inflammation in younger people likely are associated with the mRNA vaccines.

The world’s leading COVID-19 vaccines may offer lasting protection that diminishes the need for frequent booster shots.

In a rare acknowledgement, China’s top disease control official says current vaccines offer low protection against the coronavirus and mixing them is among strategies being considered to boost their effectiveness.

(AP Photo/Michael Sohn, FILE)Moderna Inc. announced Tuesday it has started testing its mRNA-1273 vaccine candidate against COVID-19 in children ages 6 months to less than 12 years old. This is part of Moderna’s Phase 2/3 vaccine study called “KidCOVE” in which is intends to enroll about 6,750 pediatric participants in theU.S. Such trials in children already were underway in children aged 12 to 15. Both Pfizer and Moderna have started these trials and expect to have results from their trials in older children this summer. A vaccine for younger children has not been expected ready until early next year (2022).

The Food and Drug Administration advisory panel unanimously voted Friday afternoon to recommend the Johnson & Johnson’s COVID-19 vaccine for an emergency use authorization. For eight hours, the group of independent experts had reviewed the safety and efficacy of the vaccine. READ: FDA finds Johnson & Johnson vaccine effectively prevents COVIDWhile the Johnson & Johnson vaccine is less effective than Pfizer and Moderna’s vaccines, the experts noted that no one who received the Johnson & Johnson vaccine was hospitalized or died from coronavirus. READ: Here’s what makes J&J vaccine different than the othersAdStudies in children are planned with the older group of children expected to begin receiving the vaccine as soon as early March. There are also additional studies planned in immunocompromised people.

The data that Johnson & Johnson submitted to the Food and Drug Administration for its emergency use authorization was made public Wednesday.

Here’s what to know about the J&J vaccine:The J&J vaccine can be stored in a normal refrigerator unlike the Pfizer and Moderna vaccines -- it’s not a mRNA vaccine. Testing, efficacyThe Johnson & Johnson vaccine has been tested on nearly 44,000 people in United States, Latin America and South Africa. Henry Ford Hospital in Detroit also was one of the clinical sites for the J&J vaccine, so many Metro Detroiters have already received the vaccine. Johnson & Johnson is running an additional trial to test effectiveness of a second dose of its vaccine. AdFeb. 24: FDA says J&J 1-dose shot prevents COVID; final decision soonFeb. 4: Johnson & Johnson asks US regulators to OK its one-shot COVID-19 vaccineMore: Local 4′s Dr. Frank McGeorge answers COVID vaccine questions

DETROIT – Since the coronavirus pandemic began, Dr. Frank McGeorge has been keeping viewers up-to-date and informed on all fronts. You should get the vaccine as close to 21 days after for the Pfizer vaccine and 28 days for the Moderna. The recommendation is to wait at least 14 days between any other vaccine and the COVID-19 vaccine. If you had significant side effects with the first dose you’ll likely have a fever with the second dose. RELATED: Tracking Michigan COVID-19 vaccine dataQuestions about coronavirus?

DETROIT – Making enough COVID-19 vaccine doses for the entire world could take years due to manufacturing challenges. They’re incredibly small, and critical to the COVID-19 vaccine rollout -- and there aren’t nearly enough of them. Whenever we reach out to our companies to ask them whether they could support manufacturing of the lipid components. For example, as soon as they hear it’s to support a COVID-19 vaccine, you know, they’re completely engaged.”Alliances are being forged in the private sector. Greenlight Biosciences, a biotech firm in Boston, has delayed the development of their mRNA vaccine candidate so they can tailor it to the newer variants of coronavirus.

Due to limited quantities of and high demand for a COVID-19 vaccine, states are planning to administer the vaccinations in multiple phases, prioritizing individuals who are at greater risk. The U.S. Food and Drug Administration (FDA) has authorized widespread use of both Pfizer’s COVID vaccine and Moderna’s COVID vaccine. MDHHS officials say that it is estimated that COVID-19 vaccines will be available to everyone who is recommended to receive it by late spring of 2021. Michigan health officials are hoping to vaccinate 70 percent of residents over the age of 18 years by the end of 2021. Initially, five Michigan hospitals would be the first to get the vaccine, according to the Michigan Health and Hospital Association.

Michigan healths officials offered an update Friday afternoon about distribution of the COVID-19 vaccine, priority groups for vaccination and efficacy and safety information currently available. Dr. Joneigh Khaldun, chief medical executive and chief deputy for health, Michigan Department of Health and Human Services (MDHHS), and Robert Swanson, MDHHS Division of Immunizations director, hosted Friday’s event. On Thursday, the Food and Drug Administration (FDA) vaccine advisory panel recommended the Pfizer COVID-19 vaccine needs to be granted an emergency use authorization. Initially, five Michigan hospitals would be the first to get the vaccine, according to the Michigan Health and Hospital Association. it’s estimated that over a period of weeks the mRNA is naturally destroyed after it has been used to produce spike proteins.

Questions about the vaccine scienceMany people have questions about the two vaccines closest to approval. Will the benefit outweigh the risk in this case?”Both the Pfizer and the Moderna vaccines are mRNA vaccines, meaning they are not live virus vaccines. it’s estimated that over a period of weeks the mRNA is naturally destroyed after it has been used to produce spike proteins. Should you get an antibody test to determine your ranking for the vaccine? Another related question is if you should get an antibody test to help determine your ranking for receiving the vaccine?

How could scientists race out COVID-19 vaccines so fast without cutting corners? A head start helped -- over a decade of behind-the-scenes research that had new vaccine technology poised for a challenge just as the coronavirus erupted. Both shots -- one made by Pfizer and BioNTech, the other by Moderna and the National Institutes of Health -- are so-called messenger RNA, or mRNA, vaccines, a brand-new technology. U.S. regulators are set to decide this month whether to allow emergency use, paving the way for rationed shots that will start with health workers and nursing home residents. Traditionally, making vaccines required growing viruses or pieces of viruses — often in giant vats of cells or, like most flu shots, in chicken eggs — and then purifying them before next steps in brewing shots.

DETROIT The first group of volunteers in Michigan to participate in the Moderna COVID-19 vaccine study received their first shots Wednesday, Henry Ford Health System announced. Henry Ford Health System is the only hospital in Michigan selected as a trial site for phase three of the Moderna mRNA-1273 Coronavirus Efficacy (COVE) vaccine study. This is a historic moment, said Dr. Marcus Zervos, division chief of Infectious Disease for Henry Ford Health System. I give them all the respect in the world.The first dose of the Moderna COVID-19 vaccine study in Michigan was administered Wednesday, Aug. 5, 2020. About 90 healthcare systems across the United States are working competitively to enroll a total of 30,000 volunteers to participate in the Moderna vaccine study.